Insider Buying: KindlyMD (NASDAQ:NAKA) CEO Acquires 55,115 Shares of Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey bought 55,115 shares of the stock in a transaction on Thursday, May 28th. The shares were bought at an average cost of $5.62 per share, with a total value of $309,746.30. Following the purchase, the chief executive officer owned 3,175,476 shares of the company’s stock, valued at $17,846,175.12. This trade represents a 1.77% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

KindlyMD Trading Up 3.7%

Shares of NASDAQ NAKA traded up $0.20 during midday trading on Thursday, hitting $5.60. The company’s stock had a trading volume of 1,023,533 shares, compared to its average volume of 228,370. The business’s fifty day simple moving average is $8.21 and its two-hundred day simple moving average is $13.07. KindlyMD, Inc. has a 1 year low of $4.50 and a 1 year high of $995.60.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($15.20) EPS for the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative return on equity of 81.32%. The business had revenue of $2.68 million during the quarter. Equities research analysts anticipate that KindlyMD, Inc. will post -16.8 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. B. Riley Financial lowered their price objective on shares of KindlyMD from $40.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. Weiss Ratings raised shares of KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. TD Cowen started coverage on KindlyMD in a report on Friday, April 10th. They set a “buy” rating and a $40.00 price target on the stock. Maxim Group cut their price target on KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Finally, Wall Street Zen upgraded KindlyMD to a “sell” rating in a report on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $30.00.

Institutional Trading of KindlyMD

Several institutional investors have recently modified their holdings of NAKA. Sagespring Wealth Partners LLC purchased a new stake in shares of KindlyMD during the 4th quarter worth approximately $28,000. SG Americas Securities LLC purchased a new stake in shares of KindlyMD during the 4th quarter worth approximately $61,000. Virtu Financial LLC purchased a new stake in shares of KindlyMD during the 4th quarter worth approximately $151,000. J. Derek Lewis & Associates Inc. purchased a new stake in shares of KindlyMD during the 4th quarter worth approximately $167,000. Finally, Truist Financial Corp purchased a new stake in shares of KindlyMD during the 4th quarter worth approximately $176,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.